We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Geddes, J, Freemantle, N, Harrisson, P, Bebbington, P.Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ2000; 321:1371–6CrossRefGoogle ScholarPubMed
[2]
Gray, JA, Feldon, J Rawlins JNP, Heursley, RR, Smith, AD. The neuropsychology of schizophrenia. Behav Brain Sci1991,14, 1-84.CrossRefGoogle Scholar
[3]
Murray, RM, Jones, PB, Sussere, E, van Os, J, Cannon, M.The epidemiology of schizophrenia. Cambridge: Cambridge University Press; 2003.Google Scholar
[4]
Tsapakis, EM, Guillin, O, Murrary, RM. Does dopamine sensitisation underlie the association between schizophrenia and drug abuse?Curr Opin Psychiatry2003;16:S45-S52.CrossRefGoogle Scholar
[5]
UK 700 Group: Burns, T, Creed, F, Faby, T, Thomson, S, Tyrer, P, White, I.Intensive versus standard case management for severe psychotic illness: a randomised trial. Lancet1999;353:2185–9.CrossRefGoogle ScholarPubMed
[6]
Wright, IC, Rabe-Hesketh, S, Wooddruff, PWR, David, AS, Murray, M, Bullmore, ET. Metat-analysis of regional brain volumes in schizophrenia. Am J Psychiatr2000;157:16–25.CrossRefGoogle Scholar
Comments
No Comments have been published for this article.